Literature DB >> 21890310

Common femoral endovenectomy with iliocaval endoluminal recanalization improves symptoms and quality of life in patients with postthrombotic iliofemoral obstruction.

David Vogel1, Anthony J Comerota, Mustafa Al-Jabouri, Zakaria I Assi.   

Abstract

BACKGROUND: The postthrombotic syndrome is a debilitating condition occurring in 30% to 50% of patients with lower extremity deep vein thrombosis (DVT). Following iliofemoral DVT, however, postthrombotic morbidity is especially severe, due to occlusion of the common femoral vein (CFV) and iliac veins. While endoluminal recanalization appears effective in restoring patency to the iliac venous system, infrainguinal obstruction of the CFV remains a problem. The purpose of this study is to report preliminary observations of common femoral endovenectomy and intraoperative endoluminal recanalization of the iliac veins in patients with incapacitating postthrombotic iliofemoral obstruction.
METHODS: Ten patients underwent common femoral endovenectomy with endoluminal iliocaval recanalization. The Venous Clinical Severity Score (VCSS), a validated tool to assess chronic venous disease, the Villalta scale, a validated tool to quantify postthrombotic syndrome, the clinical classification of CEAP, and the Venous Insufficiency Epidemiological and Economic Study-Quality of Life (VEINES-QOL)/Sym questionnaires were completed preoperatively and readministered postoperatively at 8.8 months (mean).
RESULTS: Five patients were followed for more than 6 months and form the basis of the long-term analysis. All demonstrated significant improvement in their venous scores postoperatively. The VCSS preoperatively was 17 and fell to 9.8 postoperatively (P = .02). The Villalta scale dropped from 13.6 preoperatively to 6.0 postoperatively (P = .002). The VEINES-QOL/Sym questionnaire, a sensitive marker of patient quality of life and symptom status, was improved (P = .01 and .02, respectively).
CONCLUSION: Chronic postthrombotic iliofemoral venous obstruction treated with common femoral endovenectomy and endoluminal recanalization improves objective outcome measures of patients with chronic postthrombotic obstruction. By restoring unobstructed venous drainage through the CFV to the vena cava, patients' postthrombotic morbidity is reduced and quality of life is improved.
Copyright © 2012 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21890310     DOI: 10.1016/j.jvs.2011.05.017

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  11 in total

Review 1.  Endovascular Therapy for Lower Extremity Chronic Deep Venous Occlusive Disease: State of Practice.

Authors:  Vibhor Wadhwa; Ravi N Srinivasa; Kyle J Cooper; Anthony N Hage; Jacob J Bundy; Brooke Spencer; Venu Vadlamudi; Jeffrey Forris Beecham Chick
Journal:  Semin Intervent Radiol       Date:  2018-11-05       Impact factor: 1.513

Review 2.  Central Venous Pathologies: Treatments and Economic Impact.

Authors:  Kenneth Ouriel
Journal:  Methodist Debakey Cardiovasc J       Date:  2018 Jul-Sep

3.  Endovascular therapy for advanced post-thrombotic syndrome: Proceedings from a multidisciplinary consensus panel.

Authors:  Suresh Vedantham; Susan R Kahn; Samuel Z Goldhaber; Anthony J Comerota; Sameer Parpia; Sreelatha Meleth; Diane Earp; Rick Williams; Akhilesh K Sista; William Marston; Suman Rathbun; Elizabeth A Magnuson; Mahmood K Razavi; Michael R Jaff; Clive Kearon
Journal:  Vasc Med       Date:  2016-05-30       Impact factor: 3.239

Review 4.  The Treatment of Post-Thrombotic Syndrome.

Authors:  Karina Schleimer; Mohammad Esmaeil Barbati; Alexander Gombert; Volker Wienert; Jochen Grommes; Houman Jalaie
Journal:  Dtsch Arztebl Int       Date:  2016-12-16       Impact factor: 5.594

5.  Short- and Mid-Term Outcomes of Endovascular Stenting for the Treatment of Post-Thrombotic Syndrome due to Iliofemoral and Caval Occlusive Disease: A Multi-Centric Study from the French Society of Diagnostic and Interventional Cardiovascular Imaging (SFICV).

Authors:  Arthur David; Frédéric Thony; Costantino Del Giudice; Gilles Goyault; Romaric Loffroy; Kévin Guillen; Yann Le Bras; Clément Marcelin; Valérie Monnin-Bares; Jean-François Heautot; Alexandre Lablee; Pierre Marek; Hervé Rousseau; Thomas Martinelli; Francine Thouveny; Pierre-Antoine Barral; Vincent Le Pennec; Pascal Chabrot; André Rogopoulos; Alicia Guillien; Marc Sapoval; Matthieu Rodière; Olivier Espitia; Frédéric Douane
Journal:  Cardiovasc Intervent Radiol       Date:  2022-01-04       Impact factor: 2.740

6.  Multiorgan ultrasonographic findings in patients with pulmonary embolism at diagnosis and clinical follow-up: a proof of concept study.

Authors:  Casper Falster; Gro Egholm; Niels Jacobsen; Mikael K Poulsen; Stefan Posth; Jacob E Møller; Mikkel Brabrand; Christian B Laursen
Journal:  J Ultrasound       Date:  2022-09-17

7.  Femoral Endovenectomy with Iliac Stenting for Chronic Iliofemoral Venous Occlusion.

Authors:  Won Pyo Cho; Sungsin Cho; Min-Ji Cho; Sanghyun Ahn; Sang-Il Min; Jongwon Ha; Seung-Kee Min
Journal:  Vasc Specialist Int       Date:  2017-12-31

8.  Effect of a new incision management system (PREVENA®) on wound healing after endophlebectomy of the common femoral vein: a case series.

Authors:  A Gombert; M E Barbati; C Wittens; J Grommes; H Jalaie
Journal:  J Med Case Rep       Date:  2016-05-27

Review 9.  Diagnosis and Treatment of Lower Extremity Deep Vein Thrombosis: Korean Practice Guidelines.

Authors:  Seung-Kee Min; Young Hwan Kim; Jin Hyun Joh; Jin Mo Kang; Ui Jun Park; Hyung-Kee Kim; Jeong-Hwan Chang; Sang Jun Park; Jang Yong Kim; Jae Ik Bae; Sun Young Choi; Chang Won Kim; Sung Il Park; Nam Yeol Yim; Yong Sun Jeon; Hyun-Ki Yoon; Ki Hyuk Park
Journal:  Vasc Specialist Int       Date:  2016-09-30

10.  Stent extension into a single inflow vessel is a valuable option after endophlebectomy.

Authors:  Timme Maj van Vuuren; Ralph Lm Kurstjens; Mark Af de Wolf; Jorinde Hh van Laanen; Cees Ha Wittens; Rick de Graaf
Journal:  Phlebology       Date:  2017-11-07       Impact factor: 1.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.